fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Itraconazole

Form:

5 of 5 products shown

2 general benefit · 2 Limited Use · 1 not a benefit

Jamp Itraconazole Oral Solution · DIN 02484315 · 10 mg/mL · Oral Sol

Limited Use, Reason for Use code 570 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 570 required
Write on scriptReason for Use code 570 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 570
Reason for Use code 570 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Jamp Itraconazole Oral Solution · DIN 02484315 Manufacturer: Jamp Pharma Corporation; listing date 2020-04-30 Health Canada: Marketed since 2019-07-31 · brand JAMP ITRACONAZOLE ORAL SOLUTION · ATC J02AC02 ITRACONAZOLE · form Solution · route Oral · ingredients ITRACONAZOLE 10 MG/ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Itraconazole Oral Solution: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4111). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02484315)

Source record
DIN 02484315: Jamp Itraconazole Oral Solution Raw flags: sec12=Y, sec3=Y Item: 081204043; group id 11; item number 0014; lccId 00327; manufacturer id JPC Source form: Oral Sol; strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4111; ministry $0.4111 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02484315 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97463
Interchangeable products
Odan-Itraconazole · DIN 02495988 · $0.4111 Sporanox · DIN 02231347 · not recorded
Shortage status: resolved shortage (ended April 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02484315
Shortage record checked October 6, 2026

Odan-Itraconazole · DIN 02495988 · 10 mg/mL · Oral Sol

Limited Use, Reason for Use code 570 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 570 required
Write on scriptReason for Use code 570 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 570
Reason for Use code 570 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Odan-Itraconazole · DIN 02495988 Manufacturer: Odan Laboratories Ltd.; listing date 2020-08-28 Health Canada: Marketed since 2020-07-08 · brand ODAN ITRACONAZOLE · ATC J02AC02 ITRACONAZOLE · form Solution · route Oral · ingredients ITRACONAZOLE 10 MG/ML · company Odan laboratoriesltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Odan-Itraconazole: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4111). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02495988)

Source record
DIN 02495988: Odan-Itraconazole Raw flags: sec12=Y, sec3=Y Item: 081204043; group id 11; item number 0014; lccId 00327; manufacturer id ODN Source form: Oral Sol; strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4111; ministry $0.4111 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02495988 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98587
Interchangeable products
Jamp Itraconazole Oral Solution · DIN 02484315 · $0.4111 Sporanox · DIN 02231347 · not recorded
Shortage status: resolved shortage (ended December 8, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495988
Shortage record checked October 6, 2026

Mint-Itraconazole · DIN 02462559 · 100 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Itraconazole · DIN 02462559 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-07-31 Health Canada: Marketed since 2017-05-18 · brand MINT-ITRACONAZOLE · ATC J02AC02 ITRACONAZOLE · form Capsule · route Oral · ingredients ITRACONAZOLE 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Itraconazole: Formulary list price $3.93 per unit (the source does not state the unit; exact figure $3.9270). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02462559)

Source record
DIN 02462559: Mint-Itraconazole Raw flags: sec3=Y Item: 081204040; group id 10; item number 0013; lccId None; manufacturer id MIN Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $3.9270; ministry $3.9270 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02462559 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95031
Interchangeable products
Sporanox · DIN 02047454 · $3.9270
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462559
Shortage record checked October 6, 2026

Sporanox · DIN 02047454 · 100 mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-01 — choose a marketed DIN from the same-category list.Discontinued April 1, 2026 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-04-01 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: RxHelp ONE lists Sporanox (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Sporanox · DIN 02047454 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-04-01 · brand SPORANOX · ATC J02AC02 ITRACONAZOLE · form Capsule · route Oral · ingredients ITRACONAZOLE 100 MG · company Janssen inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02047454)

Source record
DIN 02047454: Sporanox Raw flags: sec3=Y Item: 081204040; group id 10; item number 0013; lccId None; manufacturer id JAN Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $6.6750; ministry $3.9270 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02047454 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14518
Interchangeable products
Mint-Itraconazole · DIN 02462559 · $3.9270
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02047454
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 1, 2026 — choose a marketed DIN from the same-category list.

Sporanox · DIN 02231347 · 10 mg/mL · Oral Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.Discontinued September 29, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 570
Reason for Use code 570 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Sporanox (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Sporanox · DIN 02231347 Manufacturer: Janssen Inc.; listing date 1998-12-31 Health Canada: Cancelled post market since 2023-09-29 · brand SPORANOX · ATC J02AC02 ITRACONAZOLE · form Solution · route Oral · ingredients ITRACONAZOLE 10 MG/ML · company Janssen inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sporanox: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231347)

Source record
DIN 02231347: Sporanox Raw flags: notABenefit=Y, sec3=Y Item: 081204043; group id 11; item number 0014; lccId 00327; manufacturer id JAN Source form: Oral Sol; strength: 10mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231347 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50656
Interchangeable products
Jamp Itraconazole Oral Solution · DIN 02484315 · $0.4111 Odan-Itraconazole · DIN 02495988 · $0.4111
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231347
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 29, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J02A, J02AC): coverage varies; not interchangeable

  • Fluconazole (Diflucan P.O.S.): general benefit, limited Use 528, not a benefit
  • Voriconazole (Vfend): limited Use 399
  • Posaconazole (Posanol): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Caspofungin (Cancidas): not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (12) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MINT-ITRACONAZOLE (itraconazole) capsules are indicated for: • the treatment of the following systemic fungal infections in normal, predisposed or immunocompromised patients: 1. Invasive and non-invasive pulmonary aspergillosis. 2. Oral and/or esophageal candidiasis. 3. Chronic pulmonary histoplasmosis. 4. Cutaneous and lymphatic sporotrichosis. 5. Paracoccidioidomycosis. 6. Chromoblastomycosis.(formerly chromomycosis) 7. Blastomycosis. The type of organism responsible for the infection should be isolated and identified and other relevant laboratory studies (wet mount, histopathology, serology) should be undertaken as appropriate to confirm diagnosis. Therapy may be initiated prior to obtaining these results when clinically warranted; however, once these results become available, antifungal therapy should be adjusted accordingly. • the treatment of the following topical fungal infections in normal, predisposed or immunocompromised patients: 8. Dermatomycoses due to tinea corporis, tinea cruris, tinea pedis, and pityriasis versicolor, where … https://pdf.hres.ca/dpd_pm/00082400.PDF PM date: OCT 27, 2025 Source product: MINT-ITRACONAZOLE; DIN 02462559; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Sporanox · DIN 02047454 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02047454

Check this DIN again

Sporanox · DIN 02231347 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231347

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Sporanox: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026